van der Horst-Schrivers A N A, Kerstens M N, Wolffenbuttel B H R
Department of Endocrinology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Neth J Med. 2006 Sep;64(8):290-5.
Phaeochromocytoma is a rare catecholamine-secreting neuroendocrine tumour with a high cardiovascular morbidity and mortality if left untreated. Surgical resection is the only curative therapy. During surgery there is a high risk of massive release of catecholamines, which can result in potentially fatal hypertensive crises and cardiac arrhythmias. Administration of vasoactive drugs such as (non)selective alpha- and beta-antagonists and calcium channel blocking agents have reduced the operation risk. Guidelines for the preoperative medical management of the patient with a phaeochromocytoma are mainly based on retrospective studies and case reports. We reviewed the relevant literature on this subject. In addition, we compared the several preoperative treatment protocols of the eight university medical centres in the Netherlands.
嗜铬细胞瘤是一种罕见的分泌儿茶酚胺的神经内分泌肿瘤，若不治疗，心血管发病率和死亡率很高。手术切除是唯一的治愈性疗法。手术期间，儿茶酚胺大量释放的风险很高，这可能导致潜在致命的高血压危象和心律失常。使用血管活性药物，如（非）选择性α和β拮抗剂以及钙通道阻滞剂，已降低了手术风险。嗜铬细胞瘤患者术前医学管理指南主要基于回顾性研究和病例报告。我们回顾了关于该主题的相关文献。此外，我们比较了荷兰八家大学医学中心的几种术前治疗方案。
